Epiplexy is a distinct type of focal motor seizure characterized by brief, sudden, and involuntary movements that are restricted to the face and upper limb on one side of the body. The term is commonly used in the context of mesial temporal lobe epilepsy, where the hippocampus and amygdala serve as the epileptogenic focus. The following sections summarize current understanding of its definition, diagnosis, and management, and highlight recent research findings and clinical considerations.
Definition
Epiplexy (also referred to as “hemifacial and hemimandibular myoclonus” or “facial‑arm seizures”) is a focal motor seizure that originates in the temporal lobe and manifests as brief, involuntary movements limited to the contralateral facial region and upper extremity. Unlike generalized tonic–clonic or absence seizures, the activity does not typically involve the entire body, nor does it result in a generalized loss of consciousness. The hallmark features include:
- Brief (< 10 seconds) involuntary muscle contractions
- Localized to the face and arm on one side of the body
- Often preceded by a sensation of “twitching” or a brief aura
- Preserved awareness during the episode (occasionally brief confusion)
Clinical Features
During an epiplexy episode, patients may display the following signs:
- Involuntary, jerky movements of the contralateral upper lip, jaw, or cheek
- Sudden, repetitive contraction of the opposite arm or hand
- Short‑lived loss of consciousness or transient post‑ictal confusion (usually brief)
- Possible automatisms, such as repetitive grasping or mouthing, in more severe cases
Diagnostic Criteria
Identification of epiplexy relies on a combination of clinical observation, electroencephalography (EEG), and neuroimaging. The most widely accepted criteria include:
- Sudden, brief (< 10 seconds) involuntary movements restricted to the face and arm on one side of the body.
- Preserved or minimally impaired consciousness during the event.
- EEG evidence of focal ictal discharges originating from the temporal or frontal lobe, most commonly the hippocampus or amygdala.
- Neuroimaging (MRI) demonstrating structural abnormalities (e.g., mesial temporal sclerosis, focal cortical dysplasia) that correlate with the EEG seizure focus.
Patients with suspected epiplexy undergo video‑EEG monitoring to confirm the diagnosis and rule out non‑epileptic events.
Pathophysiology
In mesial temporal lobe epilepsy, epileptogenic foci arise within the hippocampus and amygdala, structures that are highly interconnected with cortical motor and limbic networks. Pathologic changes, such as neuronal loss and gliosis, create a hyperexcitable network that can produce localized motor discharges. When these discharges propagate to the corticospinal tract and affect the facial nucleus, they manifest as epiplexy.
Neuroimaging
MRI Findings
High‑resolution MRI (3 T or 7 T) typically shows characteristic changes in the hippocampus, including:
- Volume loss and reduced internal architecture
- Loss of the CA‑1 subfield and other hippocampal subfields
- Heterogeneous signal intensity on T2/FLAIR sequences
Advanced imaging techniques such as diffusion tensor imaging (DTI) and functional MRI (fMRI) further delineate microstructural and functional alterations associated with epileptogenic zones.
Functional Imaging
FDG‑PET and ictal SPECT are often used to identify hypometabolic or hyperperfused regions correlating with seizure onset. FDG‑PET typically shows interictal hypometabolism in the affected hippocampus, whereas ictal SPECT demonstrates focal hyperperfusion during an epileptic event.
Electroencephalography
Scalp EEG in epiplexy patients commonly displays:
- Focal ictal discharges over temporal or frontal electrodes
- Characteristic evolution from low‑frequency spikes to rhythmic activity
- Interictal slowing and possible rhythmic delta activity in the temporal region
High‑density EEG (≥ 64 channels) improves spatial resolution, allowing clinicians to approximate the seizure onset zone.
Treatment Options
First‑Line Antiepileptic Drugs (AEDs)
Standard treatment for mesial temporal lobe epilepsy includes sodium‑channel blockers (carbamazepine, oxcarbazepine) and second‑line agents (levetiracetam, valproate). Therapeutic drug monitoring ensures adequate plasma levels and minimizes adverse effects.
Rescue Medications
In status epilepticus, intravenous benzodiazepines (lorazepam, diazepam) are administered first, followed by propofol or midazolam infusion if seizures persist.
Surgical Management
Patients with medically refractory epiplexy and well‑localized lesions are candidates for anterior temporal lobectomy or selective amygdalohippocampectomy. Intraoperative electrocorticography and stimulation mapping guide resection while preserving critical cognitive functions.
Neuromodulation
Vagus nerve stimulation (VNS) and responsive neurostimulation (RNS) are increasingly used for patients with drug‑resistant focal seizures. Evidence indicates a 50–60 % reduction in seizure frequency for many individuals.
Adjunctive Therapies
Sleep hygiene, stress management, avoidance of known triggers, and dietary modifications (ketogenic diet) are adjunctive strategies that support seizure control.
Prognosis
Epiplexy outcomes depend on etiology and treatment approach. Mesial temporal lobe epilepsy with mesial temporal sclerosis undergoing anterior temporal lobectomy yields ~60–70 % long‑term seizure freedom. Patients with diffuse cortical involvement typically experience partial control. Improved seizure control correlates with enhanced quality of life and reduced cognitive decline.
Current Research and Emerging Therapies
Recent advances focus on:
- Genetic sequencing identifying novel ion‑channel variants linked to focal motor seizures
- Closed‑loop neuromodulation systems that detect preictal EEG signatures and deliver prophylactic stimulation
- Novel AEDs targeting metabotropic glutamate and GABA_B receptors
- High‑resolution hippocampal subfield segmentation using 7‑T MRI to refine surgical candidacy
Ongoing clinical trials aim to personalize treatment based on genetic and electrophysiological biomarkers.
Conclusion
Epiplexy represents a distinct focal motor seizure with unique clinical, electrophysiological, and neuroimaging features. Accurate diagnosis relies on integrated multimodal assessment, and timely intervention - pharmacologic, surgical, or neuromodulatory - offers the best chance for seizure control and improved patient outcomes. Continued research into underlying mechanisms and personalized treatment approaches holds promise for further improving management of epiplexy worldwide.
No comments yet. Be the first to comment!